# Liriodenine (isolated from Zanthoxylum nitidum, Enicosanthellum pulchrum, Annona diversifolia)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/liriodenine-isolated-from-zanthoxylum-nitidum-enicosanthellum-pulchrum-annona-diversifolia
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** C17H9NO2, Liriodenine (aporphine isoquinoline alkaloid from Annonaceae and Rutaceae species), oxoaporphine alkaloid, liriodenine alkaloid, oxoliriodenine, 7-oxodehydroglaucine

## Overview

Liriodenine is an oxoaporphine alkaloid that induces apoptosis in cancer cells through Bax overexpression, Bcl-2 and survivin suppression, [mitochondrial](/ingredients/condition/energy) membrane potential disruption, cytochrome c release, and S-phase cell cycle arrest. In preclinical in vitro models, it demonstrated an IC50 of 23.1–37.3 µM against CAOV-3 ovarian cancer cells over 24–72 hours, with selectivity over normal WRL-68 and SV-40 cells (IC50 >100 µM), while gold(III)-liriodenine complexes achieved IC50 values of 2–16 µM across five human tumor cell lines.

## Health Benefits

- **Anticancer Activity (Ovarian Cancer)**: Liriodenine suppressed CAOV-3 ovarian cancer cell viability with an IC50 declining from 37.3 µM at 24 hours to 23.1 µM at 72 hours, demonstrating time-dependent cytotoxicity mediated through [mitochondrial](/ingredients/condition/energy) apoptotic signaling.
- **Selective Cytotoxicity**: The compound showed markedly reduced activity against normal human hepatocyte-derived WRL-68 and SV-40 cells (IC50 >100 µM), suggesting a degree of tumor-cell selectivity that is a prerequisite for therapeutic development.
- **Topoisomerase I Inhibition**: Gold(III)-liriodenine coordination complexes ([LH][AuCl4] and [AuCl3]L) poison topoisomerase I at concentrations ≤25 µM, interfering with DNA replication and transcription in cancer cells through a mechanism distinct from the parent alkaloid alone.
- **DNA Intercalation and Electrostatic Binding**: Liriodenine and its metal complexes interact with double-stranded DNA via planar aromatic intercalation reinforced by electrostatic interactions with the phosphate backbone, contributing to genotoxic pressure that induces cancer cell apoptosis.
- **Mitochondrial Pathway Apoptosis Induction**: The compound triggers loss of mitochondrial membrane potential, cytochrome c release into the cytosol, and downstream caspase cascade activation, supported by observable chromatin condensation, membrane blebbing, and apoptotic body formation at 37 µM.
- **[Antimicrobial](/ingredients/condition/immune-support) Defense Properties**: Liriodenine is identified as a major alkaloid component in Annona diversifolia extracts studied for antimicrobial properties, contributing to the plant's phytochemical defense profile, though specific MIC values and pathogen targets require further characterization.
- **Cell Cycle Arrest**: Both free liriodenine and its gold(III) complexes induce S-phase cell cycle arrest, halting DNA synthesis in actively dividing tumor cells and providing a mechanistic basis for antiproliferative activity observed across multiple cancer cell lines.

## Mechanism of Action

Liriodenine exerts its primary antiproliferative effect through the intrinsic [mitochondrial](/ingredients/condition/energy) apoptosis pathway: it upregulates the pro-apoptotic protein Bax while downregulating the anti-apoptotic proteins Bcl-2 and survivin, shifting the cellular balance toward programmed cell death and resulting in mitochondrial membrane potential collapse and cytochrome c release into the cytoplasm. DNA fragmentation laddering observed at 37 µM after 72 hours, alongside Annexin V binding and morphological changes including membrane blebbing and chromatin condensation, collectively confirm caspase-mediated apoptotic execution. Gold(III) coordination complexes of liriodenine ([LH][AuCl4] and [AuCl3]L) introduce an additional mechanism by poisoning topoisomerase I at concentrations ≤25 µM, while the planar oxoaporphine scaffold facilitates DNA intercalation reinforced by electrostatic binding to the negatively charged phosphate backbone, compounding genotoxic stress. S-phase cell cycle arrest observed in treated cells indicates that liriodenine disrupts the fidelity of DNA synthesis, preventing tumor cell progression through the cell cycle independently of direct cytochrome c signaling.

## Clinical Summary

No clinical trials involving liriodenine in human subjects have been conducted or registered in the available scientific literature as of the time of this entry. All quantified outcome data derive from in vitro cell culture models, specifically human ovarian cancer cell lines (CAOV-3, SKOV-3) and unspecified tumor lines used in gold-complex studies, with no randomized, controlled, or observational human studies to draw from. The IC50 values reported (23–68 µM for free liriodenine; 2–16 µM for gold complexes) are in vitro metrics that cannot be directly extrapolated to effective or safe human doses without pharmacokinetic, bioavailability, and toxicology bridging studies. Confidence in any clinical application is correspondingly minimal, and liriodenine should be regarded as a lead compound in early-stage oncological drug discovery rather than a clinically validated therapeutic or nutritional supplement.

## Nutritional Profile

Liriodenine is a pure alkaloid compound (molecular formula C17H9NO2, molecular weight 259.26 g/mol) and does not contribute macronutrients, vitamins, or minerals in any meaningful nutritional sense. Its pharmacological relevance is entirely attributable to its oxoaporphine scaffold — a planar tricyclic aromatic structure with a ketone at the 7-position — which enables DNA intercalation and protein binding interactions. In whole plant sources such as Zanthoxylum nitidum, liriodenine is accompanied by other alkaloids, flavonoids, and lignans, but the concentrations of liriodenine itself are very low (approximately 0.02% of alkaloid extract), making dietary intake from whole plant consumption pharmacologically negligible. No bioavailability data exist for orally ingested liriodenine in humans, and the relevance of in vitro micromolar concentrations to any achievable plasma level through dietary or supplemental consumption has not been established.

## Dosage & Preparation

- **Isolated Alkaloid (Research Grade)**: Used exclusively in laboratory settings at concentrations of 23–70 µM in cell culture media; no oral or intravenous supplemental dose has been established for humans.
- **Traditional Herbal Preparation (Zanthoxylum nitidum)**: Root bark is decocted in water in traditional Chinese medicine practice for conditions including [inflammation](/ingredients/condition/inflammation) and cancer-related pain; liriodenine content in such preparations is not standardized and is present at very low concentrations (~0.02% of alkaloid fraction).
- **HPLC-Purified Isolate**: Obtained from Enicosanthellum pulchrum via 10–100% acetonitrile gradient chromatography, yielding approximately 8.0 mg (0.4%) per extraction batch; this form is exclusively for research use.
- **Gold(III) Coordination Complexes**: [LH][AuCl4] and [AuCl3]L complexes are synthesized chemically and studied in vitro at ≤25 µM; these are experimental compounds not available in any commercial supplement form.
- **No Commercial Supplement Form Exists**: Liriodenine is not available as a standardized dietary supplement, nutraceutical capsule, tincture, or extract product; any dose recommendation for human use would be unsupported by evidence.

## Safety & Drug Interactions

No formal human safety data, toxicology studies, maximum tolerated dose findings, or adverse event profiles exist for liriodenine, as all research has been confined to in vitro cell culture systems without progression to animal or human trials. The in vitro selectivity data showing inactivity at >100 µM in normal WRL-68 hepatocyte-derived and SV-40 cells is an encouraging preliminary signal but cannot substitute for in vivo toxicology; hepatotoxicity, nephrotoxicity, cardiotoxicity, and genotoxicity in intact organisms remain entirely uninvestigated. No drug interaction studies have been performed; however, the compound's topoisomerase I poisoning activity — shared mechanistically with camptothecin-class chemotherapeutics — raises theoretical concern for additive toxicity if combined with similar agents. Liriodenine must be considered contraindicated for self-supplementation in any population, including pregnant or lactating individuals, immunocompromised patients, and those on anticoagulant or chemotherapeutic regimens, given the complete absence of a characterized human safety envelope.

## Scientific Research

The current evidence base for liriodenine consists exclusively of in vitro preclinical studies conducted on human cancer cell lines; no animal pharmacokinetic studies, dose-escalation toxicology reports, or human clinical trials have been published in the available literature, representing a very early and limited stage of research. The most detailed study evaluated liriodenine isolated from Enicosanthellum pulchrum against CAOV-3 and SKOV-3 ovarian cancer cell lines, documenting IC50 values of 37.3±1.06 µM (24 h), 26.3±0.07 µM (48 h), and 23.1±1.62 µM (72 h) for CAOV-3, with SKOV-3 showing reduced sensitivity (IC50 68.0±1.56 µM) and normal cell lines WRL-68 and SV-40 remaining inactive at >100 µM. A separate series of investigations examined gold(III)-liriodenine coordination complexes derived from Zanthoxylum nitidum isolates, reporting IC50 values of 2–16 µM across five unspecified human tumor cell lines alongside topoisomerase I poisoning assays at ≤25 µM, though full experimental details and cell line identities were not comprehensively reported in available sources. The body of evidence is therefore characterized by small, uncontrolled in vitro experiments with no replication across independent laboratories, no in vivo validation, and no established pharmacokinetic or safety parameters, making translational interpretation premature.

## Historical & Cultural Context

Liriodenine-containing plants, particularly Zanthoxylum nitidum (known in Chinese as 两面针, liǎng miàn zhēn), have a documented history of use in traditional Chinese medicine extending several centuries, where the root bark was applied to manage pain, [inflammation](/ingredients/condition/inflammation), rheumatism, and as an adjunct treatment in folk oncological practice. The Annonaceae family, which includes Enicosanthellum pulchrum and Annona diversifolia, has broad ethnobotanical use across Southeast Asia and Mesoamerica for antipyretic, antiparasitic, and [antimicrobial](/ingredients/condition/immune-support) applications, with alkaloid-rich bark and seed extracts forming the basis of traditional remedies. Annona diversifolia, known regionally in Mexico and Central America as ilama, is consumed as a fruit and its leaves and bark have been used in indigenous medicine for gastrointestinal and infectious conditions, with alkaloids including liriodenine hypothesized to underlie some of its observed biological activities. The identification of liriodenine as a discrete chemical entity and its association with the cytotoxic properties of these plants represents a 20th-century phytochemical contribution to understanding mechanisms behind traditional uses that were practiced empirically for generations.

## Synergistic Combinations

Gold(III) coordination with liriodenine ([LH][AuCl4] and [AuCl3]L) represents the best-documented synergistic interaction, in which metal complexation reduces IC50 values to 2–16 µM compared to higher concentrations required for the free alkaloid alone, likely through augmented DNA intercalation and added topoisomerase I poisoning contributed by the gold center. Within traditional Chinese medicine formulations, Zanthoxylum nitidum preparations are frequently combined with other alkaloid-rich herbs, though liriodenine-specific combinatorial data are unavailable and such combinations have not been studied pharmacologically. No evidence-based nutraceutical stacking recommendations can be made for liriodenine at this time; any proposed synergies with other compounds such as quercetin or curcumin (which share apoptosis-inducing properties) remain entirely speculative in the absence of co-treatment studies.

## Frequently Asked Questions

### What is liriodenine and what plants is it found in?

Liriodenine is an oxoaporphine alkaloid — a planar, nitrogen-containing plant secondary metabolite — found in several plant genera including Zanthoxylum nitidum (Rutaceae) of southern China, Enicosanthellum pulchrum (Annonaceae) of Southeast Asia, and Annona diversifolia of Central America. Its concentration in plant material is very low, typically around 0.02% of the alkaloid fraction in Zanthoxylum nitidum, and it is isolated using gradient HPLC or conventional alkaloid extraction methods confirmed by UV spectroscopy at 254.5–360.5 nm.

### Does liriodenine have proven anticancer effects in humans?

No — all anticancer evidence for liriodenine comes from in vitro (cell culture) studies only, with no animal studies or human clinical trials completed or registered. In laboratory conditions, it reduced CAOV-3 ovarian cancer cell viability with an IC50 of 37.3 µM at 24 hours and 23.1 µM at 72 hours, and its gold(III) complexes achieved IC50 values of 2–16 µM in five unspecified tumor cell lines, but these results cannot be extrapolated to human treatment without pharmacokinetic and toxicology data.

### How does liriodenine kill cancer cells?

Liriodenine induces apoptosis through the intrinsic mitochondrial pathway by upregulating Bax and downregulating Bcl-2 and survivin, causing mitochondrial membrane potential collapse and cytochrome c release into the cytoplasm. Additionally, it intercalates into DNA via its planar aromatic scaffold and, when formulated as gold(III) complexes, poisons topoisomerase I at concentrations ≤25 µM — together these mechanisms arrest cancer cells in S-phase and trigger DNA fragmentation, confirmed by laddering assays at 37 µM after 72 hours.

### Is liriodenine safe to take as a supplement?

Liriodenine is not available as a commercial dietary supplement and has no established safe dose for human consumption; it should not be self-administered. While in vitro data show reduced activity against normal cells at concentrations >100 µM compared to cancer cells, there are no in vivo toxicology, pharmacokinetics, drug interaction, or human safety studies of any kind, making its risk profile in humans completely unknown.

### What is the difference between liriodenine and its gold complexes?

Free liriodenine primarily induces cancer cell apoptosis through mitochondrial pathway disruption and DNA intercalation, with IC50 values typically in the 23–68 µM range in ovarian cancer cell lines. Gold(III)-liriodenine coordination complexes — specifically [LH][AuCl4] and [AuCl3]L — add topoisomerase I poisoning to this mechanism and are roughly 4–8 times more potent in vitro, achieving IC50 values of 2–16 µM across five human tumor cell lines, likely because metal coordination amplifies DNA binding affinity and introduces additional cytotoxic mechanisms from the gold center.

### What research evidence exists for liriodenine's effectiveness against ovarian cancer?

In vitro studies demonstrate that liriodenine suppresses CAOV-3 ovarian cancer cell viability in a time-dependent manner, with IC50 values declining from 37.3 µM at 24 hours to 23.1 µM at 72 hours. The cytotoxic effect is mediated through mitochondrial apoptotic signaling pathways. However, these findings are limited to laboratory cell cultures and have not yet been validated in human clinical trials.

### Does liriodenine affect normal healthy cells differently than cancer cells?

Yes, liriodenine demonstrates selective cytotoxicity, showing markedly reduced activity against normal human hepatocyte-derived cells (WRL-68 and SV- cell lines) compared to cancer cells. This selective targeting suggests a potentially favorable safety profile for normal tissues, though further research is needed to fully characterize its effects on various healthy cell types.

### Which plant sources of liriodenine are most commonly used in supplements?

Liriodenine is primarily isolated from three plant sources: Zanthoxylum nitidum, Enicosanthellum pulchrum, and Annona diversifolia. Zanthoxylum species are among the most accessible sources and have a longer history of traditional use. The bioavailability and extract quality can vary significantly depending on the plant source and extraction method used.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*